Process validation and first in-human data of treatment with highly pure autologous ABCB5+ stem cells

Christoph Ganss

Christoph Ganss

Ex vivo-expanded highly pure ABCB5+ mesenchymal stromal cells as Good Manufacturing Practice-compliant autologous advanced therapy medicinal product for clinical use: process validation and first in-human data

Andreas Kerstan, Elke Niebergall-Roth, Jasmina Esterlechner, Hannes M. Schröder, Martin Gasser, Ana M. Waaga-Gasser, Matthias Goebeler, Katrin Rak, Philipp Schrüfer, Sabrina Endres, Petra Hagenbusch, Korinna Kraft, Kathrin Dieter, Seda Ballikaya, Nicole Stemler, Samar Sadeghi, Nils Tappenbeck, George F. Murphy, Dennis P. Orgill, Natasha Y. Frank, Christoph Ganss, Karin Scharffetter-Kochanek, Markus H. Frank, Mark A. Kluth

https://doi.org/10.1016/j.jcyt.2020.08.012
1465-3249 / © 2020 International Society for Cell & Gene Therapy. Published by Elsevier Inc.

More publications from Christoph Ganss

2021-11-05T20:03:15+01:00October 21, 2021|Other article for therapists|

Share This Story, Choose Your Platform!

Go to Top